Fimbrion awarded Phase II SBIR to Develop Novel Therapeutics to Combat Tuberculosis
CARB-X Awards Funding to GSK for the Early Clinical Development of a Novel Therapy to Treat and Prevent Recurrent Urinary Tract Infections
Oral Antibacterial Co-Developed with Fimbrion Enters Phase I Clinical Trials
Developing Powerful Alternatives to Traditional Antibiotics
Mission
Pipeline
Publications
Latest News
Janetka Named a Fellow of the National Academy of Inventors
Janetka Named a Senior Member of the National Academy of Inventors
Fimbrion Awarded Phase I SBIR to Develop Novel Therapeutics to Combat Tuberculosis
Hultgren Named to the National Academy of Inventors
Janetka Awarded the 2018 Saint Louis Award by the St. Louis Section of the American Chemical Society
Hultgren Elected to National Academy of Medicine
Fimbrion Therapeautics Pioneers Anti-Virulence Solutions to Treat UTIs
Fimbrion and GSK to Develop Novel Antibacterial Therapy for Urinary Tract Infections
Antivirulence C-Mannosides as Antibiotic-Sparing, Oral Therapeutics for Urinary Tract Infections